<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384591</url>
  </required_header>
  <id_info>
    <org_study_id>11-091</org_study_id>
    <nct_id>NCT01384591</nct_id>
  </id_info>
  <brief_title>Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly</brief_title>
  <official_title>Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lantheus Medical Imaging</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general hypothesis is that elderly have diminished nutritive flow to skeletal muscle and
      impaired capacity for building muscle. In aging populations, this decreased ability to build
      muscle may represent a tipping point in the progression towards chronic physical frailty and
      disability. The goal is to examine whether novel pharmacologic therapies can improve
      nutritive blood flow to the muscles and muscle building in the elderly.

      The purpose of this study is 1) to determine if losartan administration will enhance blood
      flow and 2) to determine if N-acetylcysteine (NAC) will enhance blood flow.

      The investigators will study community dwelling, healthy older men and women (60-85 years).
      Subjects will be randomized to one of three groups:

      Experimental Group 1: Placebo losartan and placebo N-acetylcysteine (NAC). Experimental Group
      2: losartan (25mg/dose) and placebo N-acetylcysteine (NAC). Experimental Group 3:
      N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo

      Subjects will admit to the clinic on day 1 of the study. Baseline testing consisting of leg
      blood flow (LBF), contrast enhanced ultrasound, handgrip testing and fatigue questionnaires.
      After testing is completed the subjects will recieve their first dose of NAC/ losartan/
      placebo with dinner. Subjects will be fasted after 10 pm. On day 2, leg blood flow (LBF) will
      be measured approximately 12 hours post dose 1. Subjects will receive their second dose of
      NAC/ losartan/ placebo. Leg blood flow will be measured 1 hour and 2 hours post dose 2 of
      study interventions. The subjects will eat a meal and receive their third dose of the study
      intervention. Leg blood flow will be repeated at 1 hour and 2 hours post dose 3. Appoximately
      30 minutes after dose 3 of the study intervention, handgrip testing will be performed and
      fatigue questionnaires completed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leg Blood Flow as Measured by Doppler Ultrasound</measure>
    <time_frame>Baseline</time_frame>
    <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Blood Flow as Measured by Doppler Ultrasound</measure>
    <time_frame>12 hours post dose one of the intervention</time_frame>
    <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Blood Flow as Measured by Doppler Ultrasound</measure>
    <time_frame>1 hour post dose two of the intervention, average of 13 hours post dose 1 of the intervention</time_frame>
    <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Blood Flow as Measured by Doppler Ultrasound</measure>
    <time_frame>2 hours post dose two of the intervention, average of 14 hours post dose one of the intervention</time_frame>
    <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Blood Flow as Measured by Doppler Ultrasound</measure>
    <time_frame>Post dose three of the intervention and a meal, average of 17 hours post dose one of the intervention</time_frame>
    <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Blood Flow as Measured by Doppler Ultrasound</measure>
    <time_frame>1 hour post dose three of the intervention and a meal, average of 18 hours post dose one of the intervention</time_frame>
    <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Blood Flow as Measured by Doppler Ultrasound</measure>
    <time_frame>2 hours post dose three of the intervention and a meal, average of 19 hours post dose one of the intervention</time_frame>
    <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 100% effort with subjects performing one set of three contractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 100% effort with subjects performing one set of three contractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Handgrip fatigue of dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data is reported as % of Maximal Voluntary Contraction after fatigue test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry at Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Handgrip fatigue of non-dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data is reported as % of Maximal Voluntary Contraction (MVC) after fatigue test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 100% perceived effort with subjects performing one set of three contractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 100% perceived effort with subjects performing one set of three contractions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Handgrip fatigue of dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data reported as % of Maximal Voluntary Contraction (MVC) after fatigue test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Handgrip fatigue of non-dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data reported as % of Maximal Voluntary Contraction (MVC) after fatigue test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the general fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the general fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the physical fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the physical fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the emotional fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the emotional fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the mental fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the mental fatigue scale is 24 to 0, with the higher number meaning more fatigue
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the vigor scale is 0 to 24, with the higher number meaning more vigor.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the vigor scale is 0 to 24, with the higher number meaning more vigor.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score After All Doses of Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Fatigue Score as Measured by Brief Fatigue Inventory at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The Brief Fatigue Inventory is a 9 item questionnaire that assesses perceptual fatigue as well as fatigue interferences (e.g. interference with enjoyment of life), with &quot;0&quot; being no fatigue and &quot;10&quot; being as bad as you can imagine. The Global Fatigue score is calculated by averaging the answers of all the questions. Score ranges (0 to 10) with higher score indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Fatigue Score as Measured by Brief Fatigue Inventory After Study Invention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
    <description>The Brief Fatigue Inventory is a 9 item questionnaire that assesses perceptual fatigue as well as fatigue interferences (e.g. interference with enjoyment of life), with &quot;0&quot; being no fatigue and &quot;10&quot; being as bad as you can imagine. The Global Fatigue score is calculated by averaging the answers of all the questions. Score range 0 to 10, with a higher score indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.</measure>
    <time_frame>baseline - before handgrip fatigue test</time_frame>
    <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.</measure>
    <time_frame>baseline - directly after handgrip fatigue test</time_frame>
    <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention - Before handgrip fatigue test</time_frame>
    <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention - Directly after handgrip fatigue test</time_frame>
    <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.</measure>
    <time_frame>baseline - before handgrip fatigue test</time_frame>
    <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.</measure>
    <time_frame>baseline - directly after handgrip fatigue test</time_frame>
    <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention - Before handgrip fatigue test</time_frame>
    <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention</measure>
    <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention - Directly after handgrip fatigue test</time_frame>
    <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Losartan and placebo N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo losartan and placebo N-acetylcysteine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine and placebo losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
    <arm_group_label>N-acetylcysteine and placebo losartan</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
    <arm_group_label>Losartan and placebo N-acetylcysteine</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo losartan</intervention_name>
    <description>Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
    <arm_group_label>Placebo losartan and placebo N-acetylcysteine</arm_group_label>
    <arm_group_label>N-acetylcysteine and placebo losartan</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo N-acetylcysteine</intervention_name>
    <description>Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
    <arm_group_label>Losartan and placebo N-acetylcysteine</arm_group_label>
    <arm_group_label>Placebo losartan and placebo N-acetylcysteine</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 60-85 years.

          2. Ability to sign informed consent.

          3. Ability to sign consent form.

          4. Ability to pass a mini-mental status exam (score &gt;23 on the 30-item Mini Mental State
             Examination, MMSE).

          5. Free-living, prior to admission.

        Exclusion Criteria:

          1. Subjects with cardiac abnormalities considered exclusionary by the study physicians
             (e.g., unstable angina or a cardiology-confirmed ECG that demonstrates cardiac
             abnormalities such as &gt; 0.2 mV horizontal or downsloping ST segment depression,
             frequent arrhythmia's (&gt; 10 PVC/min), or valvular disease).

          2. Subjects with uncontrolled metabolic disease, including liver or renal disease.

          3. Subjects with vascular disease characterized by a combination of risk factors of
             peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, uncontrolled
             diabetes, hypercholesterolemia &gt; 250 mg/dl, claudication or evidence of venous or
             arterial insufficiency upon palpitation of femoral, popliteal, and pedal arteries.

          4. Any history of hypo- or hyper-coagulation disorders. (e.g., Coumadin use or history of
             DVT or PE).

          5. Subjects with chronically elevated systolic pressure &gt;170 or a diastolic blood
             pressure &gt; 100. Subjects may be included if they are taking medication and have a
             blood pressure below these criteria.

          6. Subjects with cancer or recently (6 months) treated cancer other than basal cell
             carcinoma.

          7. Any subject currently on a weight-loss diet or a body mass index &gt; 33 kg/m2.

          8. Inability to abstain from smoking for duration of study.

          9. A history of &gt; 20 pack per year smoking.

         10. Subjects with atrial fibrillation, history of syncope, angina, or congestive heart
             failure.

         11. Any subject that is HIV-seropositive or has active hepatitis.

         12. Recent anabolic or corticosteroids use (within 3 months).

         13. Subjects with low hemoglobin or hematocrit (i.e., lower than accepted lab values).

         14. Agitation/aggression disorder.

         15. Dementia.

         16. History of stroke with motor disability.

         17. A recent history (&lt;12 months) of GI bleed.

         18. Alcohol (more than 3 drinks per day) or drug abuse.

         19. Polycystic ovary syndrome (PCOS) and/or hyperthecosis.

         20. Non-classical adrenal hyperplasia.

         21. Cushing's syndrome.

         22. Pregnancy.

         23. Hyperprolactinoma, hypothyroidism.

         24. Lactose intolerance.

         25. Subjects with coronary heart or mitral valvular rheumatic heart disease.

         26. Subjects with impaired renal function and/or renal artery stenosis.

         27. Subjects with pulmonary hypertension.

         28. Subjects on any medications known to vasodilate the peripheral arteries.

         29. Subjects taking NSAIDs

         30. Physical dependence or frailty (impairment of activities of daily living, ADLs).

         31. History of falls (&gt;2/year).

         32. Depression (&gt;5 of the 15 items on the Geriatric Depression Scale (GDS).

         33. Subjects suffering malnutrition or with a BMI &lt; 20 kg/m2 with low albumin or
             transferrin.

         34. Asthma

         35. Any other condition or event considered exclusionary by the PI and covering faculty
             physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melinda Sheffield-Moore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTMB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Astrid M Horstman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UTMB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <results_first_submitted>February 23, 2018</results_first_submitted>
  <results_first_submitted_qc>April 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2018</results_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxidative stress</keyword>
  <keyword>blood flow</keyword>
  <keyword>antioxidant</keyword>
  <keyword>muscle</keyword>
  <keyword>elderly</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Losartan and Placebo N-acetylcysteine</title>
          <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Losartan and Placebo N-acetylcysteine</title>
          <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
        </group>
        <group group_id="P3">
          <title>N-acetylcysteine and Placebo Losartan</title>
          <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan and Placebo N-acetylcysteine</title>
          <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Losartan and Placebo N-acetylcysteine</title>
          <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
        </group>
        <group group_id="B3">
          <title>N-acetylcysteine and Placebo Losartan</title>
          <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.2" spread="3.6"/>
                    <measurement group_id="B2" value="72.3" spread="2.1"/>
                    <measurement group_id="B3" value="68.5" spread="1.3"/>
                    <measurement group_id="B4" value="72" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Mass</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="10.2"/>
                    <measurement group_id="B2" value="72.7" spread="11.4"/>
                    <measurement group_id="B3" value="65.7" spread="3.5"/>
                    <measurement group_id="B4" value="68.5" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lean Body Mass</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="11.1"/>
                    <measurement group_id="B2" value="52.9" spread="14.2"/>
                    <measurement group_id="B3" value="45.9" spread="2.4"/>
                    <measurement group_id="B4" value="46.7" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat Mass</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="0.98"/>
                    <measurement group_id="B2" value="16.6" spread="3.2"/>
                    <measurement group_id="B3" value="16.8" spread="0.490"/>
                    <measurement group_id="B4" value="19.1" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
        <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
          <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
          <units>ml/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.99" spread="176.02"/>
                    <measurement group_id="O2" value="102.08" spread="3.42"/>
                    <measurement group_id="O3" value="428.45" spread="114.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
        <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
        <time_frame>12 hours post dose one of the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
          <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
          <units>ml/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.88" spread="204.92"/>
                    <measurement group_id="O2" value="69.83" spread="77.57"/>
                    <measurement group_id="O3" value="91.68" spread="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
        <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
        <time_frame>1 hour post dose two of the intervention, average of 13 hours post dose 1 of the intervention</time_frame>
        <population>Missed blood flow measurement on one placebo participant at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
          <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
          <population>Missed blood flow measurement on one placebo participant at this time point.</population>
          <units>ml/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.80"/>
                    <measurement group_id="O2" value="90.06" spread="39.19"/>
                    <measurement group_id="O3" value="95.60" spread="64.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
        <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
        <time_frame>2 hours post dose two of the intervention, average of 14 hours post dose one of the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
          <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
          <units>ml/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.56" spread="88.42"/>
                    <measurement group_id="O2" value="70.37" spread="15.35"/>
                    <measurement group_id="O3" value="114.34" spread="38.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
        <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
        <time_frame>Post dose three of the intervention and a meal, average of 17 hours post dose one of the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
          <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
          <units>ml/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.71" spread="83.85"/>
                    <measurement group_id="O2" value="109.94" spread="59.51"/>
                    <measurement group_id="O3" value="153.38" spread="103.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
        <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
        <time_frame>1 hour post dose three of the intervention and a meal, average of 18 hours post dose one of the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
          <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
          <units>ml/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.41" spread="18.57"/>
                    <measurement group_id="O2" value="104.40" spread="56.55"/>
                    <measurement group_id="O3" value="152.10" spread="46.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
        <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
        <time_frame>2 hours post dose three of the intervention and a meal, average of 19 hours post dose one of the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Blood Flow as Measured by Doppler Ultrasound</title>
          <description>Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers. A pulsed-wave Doppler sample blood volume will be placed at the same location in the center of the artery, and the mean blood velocity will be measured using online angle correction and analysis software. Femoral artery mean blood flow will be calculated from 2-D and Doppler ultrasound data using the equation: Q = vπ ∙ (d/2)2, where Q is femoral blood flow, v is mean femoral artery blood flow velocity, and d is femoral artery diameter.</description>
          <units>ml/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.60" spread="17.46"/>
                    <measurement group_id="O2" value="128.78" spread="123.74"/>
                    <measurement group_id="O3" value="57.79" spread="29.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline</title>
        <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline</title>
          <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="6.5"/>
                    <measurement group_id="O2" value="23.2" spread="4.9"/>
                    <measurement group_id="O3" value="20.5" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline</title>
        <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort at Baseline</title>
          <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="2.6"/>
                    <measurement group_id="O2" value="19.3" spread="1.9"/>
                    <measurement group_id="O3" value="17.0" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline</title>
        <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 100% effort with subjects performing one set of three contractions.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline</title>
          <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 100% effort with subjects performing one set of three contractions.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="8.2"/>
                    <measurement group_id="O2" value="33.2" spread="4.0"/>
                    <measurement group_id="O3" value="28.8" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline</title>
        <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 100% effort with subjects performing one set of three contractions.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Effort at Baseline</title>
          <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 100% effort with subjects performing one set of three contractions.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" spread="7.9"/>
                    <measurement group_id="O2" value="31.1" spread="0.8"/>
                    <measurement group_id="O3" value="26.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry at Baseline</title>
        <description>Handgrip fatigue of dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data is reported as % of Maximal Voluntary Contraction after fatigue test.</description>
        <time_frame>baseline</time_frame>
        <population>Data for 2 subjects wasn't recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry at Baseline</title>
          <description>Handgrip fatigue of dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data is reported as % of Maximal Voluntary Contraction after fatigue test.</description>
          <population>Data for 2 subjects wasn't recorded.</population>
          <units>% of Maximal Voluntary Contraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.6"/>
                    <measurement group_id="O2" value="94.2" spread="12.06"/>
                    <measurement group_id="O3" value="103.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry at Baseline</title>
        <description>Handgrip fatigue of non-dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data is reported as % of Maximal Voluntary Contraction (MVC) after fatigue test.</description>
        <time_frame>baseline</time_frame>
        <population>Data for 2 subjects was not recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry at Baseline</title>
          <description>Handgrip fatigue of non-dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data is reported as % of Maximal Voluntary Contraction (MVC) after fatigue test.</description>
          <population>Data for 2 subjects was not recorded.</population>
          <units>% of Maximal Voluntary Contraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.55"/>
                    <measurement group_id="O2" value="83.62" spread="2.33"/>
                    <measurement group_id="O3" value="90.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention</title>
        <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention</title>
          <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="13.9"/>
                    <measurement group_id="O2" value="15.8" spread="1.6"/>
                    <measurement group_id="O3" value="16.2" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention</title>
        <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 50% Perceived Effort After All Doses of Study Intervention</title>
          <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 50% perceived effort with subjects performing one set of three contractions.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="4.5"/>
                    <measurement group_id="O2" value="14.8" spread="4.5"/>
                    <measurement group_id="O3" value="13.7" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention</title>
        <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 100% perceived effort with subjects performing one set of three contractions.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Strength of Dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention</title>
          <description>Handgrip Strength of dominant hand is measured by handgrip dynamometry at 100% perceived effort with subjects performing one set of three contractions.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="6.2"/>
                    <measurement group_id="O2" value="31.3" spread="6.6"/>
                    <measurement group_id="O3" value="24.2" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention</title>
        <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 100% perceived effort with subjects performing one set of three contractions.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Strength of Non-dominant Hand as Measured by Handgrip Dynamometry at 100% Perceived Effort After All Doses of Study Intervention</title>
          <description>Handgrip Strength of non-dominant hand is measured by handgrip dynamometry at 100% perceived effort with subjects performing one set of three contractions.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="3.9"/>
                    <measurement group_id="O2" value="28.6" spread="2.7"/>
                    <measurement group_id="O3" value="30.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention</title>
        <description>Handgrip fatigue of dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data reported as % of Maximal Voluntary Contraction (MVC) after fatigue test.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <population>Data for 2 subjects not recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Fatigue of Dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention</title>
          <description>Handgrip fatigue of dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data reported as % of Maximal Voluntary Contraction (MVC) after fatigue test.</description>
          <population>Data for 2 subjects not recorded.</population>
          <units>% of Maximal Voluntary Contraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.0"/>
                    <measurement group_id="O2" value="95.97" spread="2.16"/>
                    <measurement group_id="O3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention</title>
        <description>Handgrip fatigue of non-dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data reported as % of Maximal Voluntary Contraction (MVC) after fatigue test.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <population>Data from 2 subjects was not recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Handgrip Fatigue of Non-dominant Hand as Measured by Handgrip Dynamometry After All Doses of Study Intervention</title>
          <description>Handgrip fatigue of non-dominant hand as measured by handgrip dynamometry fatigue test. The non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes. Data reported as % of Maximal Voluntary Contraction (MVC) after fatigue test.</description>
          <population>Data from 2 subjects was not recorded.</population>
          <units>% of Maximal Voluntary Contraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.61"/>
                    <measurement group_id="O2" value="93.25" spread="11.32"/>
                    <measurement group_id="O3" value="95.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue at Baseline</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the general fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue at Baseline</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the general fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="1.5" spread="2.12"/>
                    <measurement group_id="O3" value="3.5" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue After All Doses of Study Intervention</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the general fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale General Fatigue After All Doses of Study Intervention</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the general fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="2" spread="2.8"/>
                    <measurement group_id="O3" value="6.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue at Baseline</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the physical fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue at Baseline</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the physical fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.7"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                    <measurement group_id="O3" value="3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue After All Doses of Study Intervention</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the physical fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Physical Fatigue After All Doses of Study Intervention</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the physical fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                    <measurement group_id="O3" value="7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue at Baseline</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the emotional fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue at Baseline</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the emotional fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.7"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="4" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue After All Doses of Study Intervention</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the emotional fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Emotional Fatigue After All Doses of Study Intervention</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the emotional fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.7"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="7.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue at Baseline</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the mental fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue at Baseline</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the mental fatigue scale is 24 to 0, with the higher number meaning more fatigue.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.7"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                    <measurement group_id="O3" value="4.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue After All Doses of Study Intervention</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the mental fatigue scale is 24 to 0, with the higher number meaning more fatigue
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Mental Fatigue After All Doses of Study Intervention</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the mental fatigue scale is 24 to 0, with the higher number meaning more fatigue
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="1" spread="1.4"/>
                    <measurement group_id="O3" value="6.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue at Baseline</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the vigor scale is 0 to 24, with the higher number meaning more vigor.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue at Baseline</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the vigor scale is 0 to 24, with the higher number meaning more vigor.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="0"/>
                    <measurement group_id="O2" value="15" spread="2.8"/>
                    <measurement group_id="O3" value="16.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue After All Doses of Study Intervention</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the vigor scale is 0 to 24, with the higher number meaning more vigor.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Subscale Vigor Fatigue After All Doses of Study Intervention</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the vigor scale is 0 to 24, with the higher number meaning more vigor.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="3.5"/>
                    <measurement group_id="O2" value="15.5" spread="3.5"/>
                    <measurement group_id="O3" value="14" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score at Baseline</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score at Baseline</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" spread="2.12"/>
                    <measurement group_id="O2" value="-12.5" spread="6.36"/>
                    <measurement group_id="O3" value="-1.5" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score After All Doses of Study Intervention</title>
        <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Personal Perceptual Fatigue Measured by Multidimensional Fatigue Symptom Inventory - Total Score After All Doses of Study Intervention</title>
          <description>Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF) from the Moffitt Cancer Center, University of South Florida The MFSI-SF is a 30 question assessment designed to assess the principal manifestations of fatigue.
There 5 subscales used to calculate a total score. The subscales are: General Fatigue, Physical Fatigue, Emotional Fatigue, Mental Fatigue, and Vigor (an estimate of the patient's energy level). The total score is calculated with the equation: (general + physical + emotional + mental) - vigor = total score.
The range of the total score is -24 to 96, with the higher the number meaning more fatigue.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20" spread="2.8"/>
                    <measurement group_id="O2" value="-12" spread="1.4"/>
                    <measurement group_id="O3" value="13.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Fatigue Score as Measured by Brief Fatigue Inventory at Baseline</title>
        <description>The Brief Fatigue Inventory is a 9 item questionnaire that assesses perceptual fatigue as well as fatigue interferences (e.g. interference with enjoyment of life), with &quot;0&quot; being no fatigue and &quot;10&quot; being as bad as you can imagine. The Global Fatigue score is calculated by averaging the answers of all the questions. Score ranges (0 to 10) with higher score indicating a worse outcome.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Fatigue Score as Measured by Brief Fatigue Inventory at Baseline</title>
          <description>The Brief Fatigue Inventory is a 9 item questionnaire that assesses perceptual fatigue as well as fatigue interferences (e.g. interference with enjoyment of life), with &quot;0&quot; being no fatigue and &quot;10&quot; being as bad as you can imagine. The Global Fatigue score is calculated by averaging the answers of all the questions. Score ranges (0 to 10) with higher score indicating a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.78"/>
                    <measurement group_id="O2" value="0.38" spread="0.39"/>
                    <measurement group_id="O3" value="1.11" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Fatigue Score as Measured by Brief Fatigue Inventory After Study Invention</title>
        <description>The Brief Fatigue Inventory is a 9 item questionnaire that assesses perceptual fatigue as well as fatigue interferences (e.g. interference with enjoyment of life), with &quot;0&quot; being no fatigue and &quot;10&quot; being as bad as you can imagine. The Global Fatigue score is calculated by averaging the answers of all the questions. Score range 0 to 10, with a higher score indicating a worse outcome.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Fatigue Score as Measured by Brief Fatigue Inventory After Study Invention</title>
          <description>The Brief Fatigue Inventory is a 9 item questionnaire that assesses perceptual fatigue as well as fatigue interferences (e.g. interference with enjoyment of life), with &quot;0&quot; being no fatigue and &quot;10&quot; being as bad as you can imagine. The Global Fatigue score is calculated by averaging the answers of all the questions. Score range 0 to 10, with a higher score indicating a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.7"/>
                    <measurement group_id="O2" value="0.22" spread="0.31"/>
                    <measurement group_id="O3" value="1.19" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.</title>
        <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
        <time_frame>baseline - before handgrip fatigue test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.</title>
          <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.14"/>
                    <measurement group_id="O2" value="3.3" spread="2.69"/>
                    <measurement group_id="O3" value="0.2" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.</title>
        <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
        <time_frame>baseline - directly after handgrip fatigue test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.</title>
          <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.39"/>
                    <measurement group_id="O2" value="7.5" spread="4.5"/>
                    <measurement group_id="O3" value="0.6" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention</title>
        <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention - Before handgrip fatigue test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention</title>
          <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="1.62"/>
                    <measurement group_id="O2" value="1" spread="1.41"/>
                    <measurement group_id="O3" value="0.65" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention</title>
        <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention - Directly after handgrip fatigue test</time_frame>
        <population>Data for 1 subject was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigue of Non-dominant Arm as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention</title>
          <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
          <population>Data for 1 subject was not collected.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="4.38"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0.75" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.</title>
        <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
        <time_frame>baseline - before handgrip fatigue test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test at Baseline.</title>
          <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.14"/>
                    <measurement group_id="O2" value="1.15" spread="0.35"/>
                    <measurement group_id="O3" value="0.55" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.</title>
        <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
        <time_frame>baseline - directly after handgrip fatigue test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test at Baseline.</title>
          <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="1.20"/>
                    <measurement group_id="O2" value="5" spread="3.11"/>
                    <measurement group_id="O3" value="0.6" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention</title>
        <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention - Before handgrip fatigue test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale Before Handgrip Fatigue Test After Study Intervention</title>
          <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.42"/>
                    <measurement group_id="O2" value="4.1" spread="4.1"/>
                    <measurement group_id="O3" value="0.55" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention</title>
        <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
        <time_frame>Post dose three of the intervention, average of 17 hours post dose one intervention - Directly after handgrip fatigue test</time_frame>
        <population>Data for 1 subject was not recorded</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Losartan and Placebo N-acetylcysteine</title>
            <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O2">
            <title>N-acetylcysteine and Placebo Losartan</title>
            <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
          <group group_id="O3">
            <title>Losartan and Placebo N-acetylcysteine</title>
            <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Perceptual Fatigue of Whole Body as Measured by Visual Analog Scale After Handgrip Fatigue Test After Study Intervention</title>
          <description>The Visual Analog Scale for Fatigue is an 11cm long line. The subject is asked to mark their level of fatigue (0cm being no fatigue and 11cm being extreme fatigue). This test was performed before and after the handgrip fatigue test, where the non-dominant hand hold a continuous contraction at 20% of the subjects maximal voluntary contraction for 5 minutes.
Handgrip testing was performed at baseline (before any intervention) and post dose three of the intervention, average of 17 hours post dose one intervention.</description>
          <population>Data for 1 subject was not recorded</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.34"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="0.95" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Losartan and Placebo N-acetylcysteine</title>
          <description>Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
        </group>
        <group group_id="E2">
          <title>N-acetylcysteine and Placebo Losartan</title>
          <description>N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
N-acetylcysteine: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo losartan: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
        </group>
        <group group_id="E3">
          <title>Losartan and Placebo N-acetylcysteine</title>
          <description>losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
Losartan: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
Placebo N-acetylcysteine: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash after infusion with Definity</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melinda Sheffield-Moore</name_or_title>
      <organization>University of Texas Medical Branch</organization>
      <phone>409-772-8126</phone>
      <email>melmoore@utmb.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

